Reuters logo
3 个月内
BRIEF-Crispr, Intellia, Caribou Biosciences, ERS Genomics announce appeal of CRISPR/CAS9 U.S. patent board decision
2017年4月13日 / 中午11点48分 / 3 个月内

BRIEF-Crispr, Intellia, Caribou Biosciences, ERS Genomics announce appeal of CRISPR/CAS9 U.S. patent board decision

1 分钟阅读

April 13 (Reuters) - Crispr Therapeutics Ag

* Crispr Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics announce appeal of CRISPR/CAS9 U.S. patent board decision

* Crispr Therapeutics AG - appeal to U.S. Court of Appeals for federal circuit seeks review and reversal of patent trial

* Crispr Therapeutics AG - appeals board's decision to terminate CRISPR/CAS9 interference

* Crispr Therapeutics AG - companies and their licensors plan to pursue additional patents in U.S. and worldwide covering CRISPR/CAS9 technology Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below